QIAGEN Launches New Secondary Analysis Solution Tailored for Oncology and Inherited Disease Bioinformatics Workflows
Overview
QIAGEN has introduced QCI Secondary Analysis, a cloud-based software-as-a-service (SaaS) solution that facilitates high-throughput secondary analysis for clinical next-generation sequencing (NGS) data. This platform seamlessly integrates with QCI Interpret, QIAGEN's clinical variant interpretation and reporting software, and supports all QIAGEN QIAseq panels.
Sequencing Data
- Traditionally, sequencing data goes through three phases: primary analysis, secondary analysis, and tertiary analysis.
- QCI Secondary Analysis focuses on the secondary analysis stage, where DNA fragments are assembled and analyzed for variants in relation to a reference genome.
- This tool simplifies the bioinformatics pipeline, making NGS testing more accessible to labs of varying sizes and expertise levels.
- The platform is designed to streamline analysis from various assay types, minimizing resource investment while maximizing productivity.
- It is deployed on the secure QIAGEN Clinical Cloud, ensuring data protection and compliance with regulatory standards such as ISO 27001, GDPR, and HIPAA.
Support for QIAseq Panels
- QCI Secondary Analysis complements QIAGEN's Sample to Insight portfolio, providing validated support for QIAseq panels, integration with QCI Interpret, and compatibility with other QIAGEN software modules like LightSpeed Clinical.
- QIAGEN Digital Insights solutions empower researchers and clinicians worldwide, facilitating data processing and interpretation for improved research outcomes.
QCI Secondary Analysis
- For labs interested in leveraging comprehensive genomic information, QCI Secondary Analysis offers a user-friendly, turnkey solution.
- With its ability to process more sequencing data efficiently, this platform represents a significant advancement in precision medicine accessibility.
